Answers are grounded in this paper and cite their sources.
Achromobacter xylosoxidans is an emerging pathogen in cystic fibrosis patients. The multidrug resistance of these bacteria remains poorly understood. We have characterized in a clinical strain the first resistance-nodulation-cell division (RND)-type multidrug efflux pump in this species: AxyABM. The inactivation of the transporter component axyB gene led to decreased MICs of cephalosporins (except cefepime), aztreonam, nalidixic acid, fluoroquinolones, and chloramphenicol.
No takes yet. Share an insight, caveat, or question.
Bador et al. (2011) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: